Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tremeau Pharmaceuticals

Request full access

A privately funded clinical stage company based Massachusetts

Concord, United StatesFounded 2016Biotech & Life Sciences

About Tremeau Pharmaceuticals

Founded in 2016 by Bradford C. Sippy, Tremeau Pharmaceuticals is a privately held, venture capital-backed pharmaceutical company headquartered in Concord, Massachusetts. The company's name honors the founder's ancestor, Joseph Tremeau, a French soldier wounded in the American Revolutionary War. Bradford C. Sippy, who serves as CEO, is an experienced pharmaceutical executive with a background in chemical engineering and an MBA, who previously managed blockbuster drugs like LATUDA and LUNESTA before starting Tremeau.

Tremeau operates within the drug discovery and pharmaceuticals industry, concentrating on the development of non-opioid pain therapies. Its business model is centered on identifying and repurposing established drugs for well-defined patient populations with significant unmet medical needs, particularly those for whom traditional NSAIDs or opioids are not suitable. The company has secured significant financing, including a $5.2 million equity round in 2018 and a total of $115 million raised to support its clinical programs. This funding is used to advance its pipeline through the FDA's regulatory process.

The company's lead product candidate is TRM-201, a formulation of rofecoxib, which was previously marketed as VIOXX before being voluntarily withdrawn by Merck in 2004 due to cardiovascular risks associated with long-term, high-dosage use. Tremeau is developing TRM-201 as a non-opioid analgesic for specific conditions where its benefits could outweigh the risks. One primary focus is the treatment of hemophilic arthropathy (HA), a degenerative joint disease in hemophilia patients for which there are no currently approved treatments in the U.S. and opioids are the standard of care. TRM-201 received Orphan Drug Designation from the FDA for this indication in 2017. The key differentiator of rofecoxib is that it is a COX-2 selective NSAID, meaning it does not affect platelet aggregation, reducing the risk of gastrointestinal bleeding compared to traditional NSAIDs—a critical feature for patients with bleeding disorders. Tremeau is also pursuing the use of TRM-201 for the acute treatment of migraine and has received FDA clearance to begin a Phase III program.

Source: Dealroom company data

Tremeau Pharmaceuticals in the Concord ecosystem

Live from Dealroom

The Tremeau Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

  • Gurnet Point Capital
  • Ernesto Bertarelli
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tremeau Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tremeau Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.